Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:6.2.1.1 (ACS)
 78,556 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A novel type of core-shell chitosan microcapsule with programmed sequential drug release is developed by the microfluidic technique for acute gastrosis therapy. The microcapsule is composed of a cross-linked chitosan hydrogel shell and an oily core containing both free drug molecules and drug-loaded poly(lactic-co-glycolic acid) (PLGA) nanoparticles. Before exposure to acid stimulus, the resultant microcapsules can keep their structural integrity without leakage of the encapsulated substances. Upon acid-triggering, the microcapsules first achieve burst release due to the acid-induced decomposition of the chitosan shell. The encapsulated free drug molecules and drug-loaded PLGA nanoparticles are rapidly released within 60 s. Next, the drugs loaded in the PLGA nanoparticles are slowly released for several days to achieve sustained release based on the synergistic effect of drug diffusion and PLGA degradation. Such core-shell chitosan microcapsules with programmed sequential drug release are promising for rational drug delivery and controlled-release for the treatment of acute gastritis. In addition, the microcapsule systems with programmed sequential release provide more versatility for controlled release in biomedical applications.
ACS Appl Mater Interfaces 2016 04 27
PMID:Core-Shell Chitosan Microcapsules for Programmed Sequential Drug Release. 2705 12